Abstract
Overview
Introduction
Almost 100 million post-menopausal women suffer from osteopenia and
osteoporosis in the seven major markets. Those diagnosed are often identified
through screening for low bone mineral density or after presenting with a
fracture. Although not all guidelines are clear on when to initiate
pharmacological treatment, most base their assessment of the type of drug to
treat with on cost-benefit analyses
Scope
- Patient segmentation by disease severity as defined by the WHO; including
osteopenia, osteoporosis, and severe/established osteoporosis
- Analysis of presentation, diagnosis, and treatment trends as well patient
referral pathways in each of the major regions
- Treatment trends split by line of therapy and disease severities,
including drug switching behaviors in each of the seven major market regions
- Prescriber scoring of key drug brands on factors including efficacy, side
effects, dosing flexibility, formulations, patient compliance, and cost
Report Highlights
The asymptomatic characteristics of osteoporosis, the fact that the majority
of fractures remain undetected and the lack of nationwide screening means that
osteoporosis is severely under-diagnosed.
About two-thirds of the patients are treated initially by a specialist and
stay with the specialist for long-term treatment across the seven major
markets, although a small group of patients switch from initial treatment by a
specialist to long-term treatment under their general practitioner
The most important factors that physicians consider when prescribing drugs for
osteoporosis are efficacy on bone mineral density and fracture risk reduction.
Bisphosphonates reached similar scores on efficacy and safety in Datamonitor' s
physician survey, but are differentiated in terms of cost, flexibility of
administration, and intermittent dosing
Reasons to Purchase
- Target physicians more effectively through an understanding of prescribing
behavior and its influences.
- Validate new product forecasting based on diagnosis and treatment rates,
and the likely rate of uptake for new products
- Benchmark brand awareness and perceptions surrounding product positioning
in order to formulate competitive lifecycle management strategies.
| 
View Cart
